Israel Biotech Fund (IBF), founded by Dr. David Sidransky, Dr. Yuval Cabilly and Ido Zairi, announced the closing of its second fund with a total of $112 million. The fund will focus on the investment and formation of Israeli biotech and pharma companies developing drugs at different stages of development and for various indications. Amongst the main limited partners of fund II are Harel Insurance, BMS, an international pharmaceutical company, and the CBG fund. The second fund will continue its collaboration with the international advisory team of the fund, which includes, among others, Dr. Sol Barer, founder of Celgene and Chairman of Teva, and Jeff Kindler, former CEO of Pfizer.
The Bank of Israel inaugurates new Open Finance infrastructure thepaypers.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepaypers.com Daily Mail and Mail on Sunday newspapers.
Pfizer, AstraZeneca Selected To Establish New Innovation Lab
By NoCamels Team
December 30, 2020 2 minutes
The Israel Innovation Authority (IIA) and the National Digital Ministry have selected pharmaceutical companies Pfizer, AstraZeneca, Merck, and Teva to establish an Innovation Lab in order to research digital health and computational biology. The group will establish the lab at Rehovot Science Park.
The companies will join the Israel Biotech Fund and Amazon Web Services (AWS) to “assist early-stage entrepreneurs and startups to meet the challenges of the healthcare industry,” an IIA announcement said.
The lab is scheduled to open in 2021 and will join existing innovation labs as part of the Israel Innovation Authority’s Innovation Lab Program. It was awarded a government budget of NIS 32 million ($9.9 million), as well as additional financing from the winning group’s partners. The group was awarded a five-year operational franchise, and the IIA and National Digita
Aharon Aharon, CEO of the Israel Innovation Authority (Courtesy)
The lab is scheduled to open in 2021, and will be part of the innovation labs program set up by the Innovation Authority in 2017. The program seeks to prod international corporations into setting up these labs to support startups in their field of interest and to take part in the Israeli ecosystem by gaining exposure to a variety of innovative developments. For startup entrepreneurs, the labs present an opportunity to access technological infrastructure, market insights and industry expertise.
The consortium of the global pharma firms was selected via a competitive process held by the Innovation Authority together with the National Digital Ministry.
The Israel Innovation Authority (IIA) and the National Digital Ministry have selected Pfizer, AstraZeneca, Merck, and Teva to establish an Innovation Lab to research digital health and computational biology. The companies, which join the presence of the Israel Biotech Fund and Amazon Web Services (AWS), will establish the laboratory at Rehovot Science Park to help entrepreneurs and startups meet the challenges of the healthcare industry.
The lab is scheduled to open in 2021 and will join existing labs as part of the program initiated by the IIA. In total, it will have a government budget of NIS 32 million ($9.9 million) as well as additional funding from the group’s partners. The group was awarded a five-year operational franchise and the IIA and National Digital Ministry will finance 85% of a NIS 3 million ($1 million) budget for each startup that joins the lab.